Skip to Content
Jump to the top of the page

Insights

Statistical analysis and insight into activity and trends in M&A and capital markets.

Close up of people looking at some papers

Recent Investment Banking Insights

  • The Quarterly Rx: Q2 2025 U.S. Biopharma Recap

    The second quarter was another rollercoaster period for biopharma, opening with “Liberation Day” and closing amid mounting macro and geopolitical uncertainty.

    Read more
  • Why Mexico is Positioned Well as Global Trade Evolves

    Shifting U.S. tariff policies—combined with continuing nearshoring trends—have Mexico in a strong position relative to other countries, with major ramifications for the transportation and logistics sector.

    Read more
  • No ‘Pencils Down’ in Secondaries, Despite Tariff Shocks

    Confidence in the secondary market remains high—even if trade-related uncertainty remains—with investors saying they are “still open for business” and that they “won’t be going pencils down.”

    Read more
  • Aviation Services Industry Update

    U.S. general aviation held steady in the first quarter while business jet and fractional activity saw notable gains—set against a broader backdrop of continued growth in global commercial air passenger traffic.

    Read more
  • Critical Tariff-Related M&A Due Diligence Questions

    Recent tariff-related disruptions have significantly expanded the scope of M&A due diligence, with buyers now asking target companies an array of questions to assess new trade policy risk.

    Read more
  • The Right Platform for This Moment

    Amid the evolving economic landscape of the past few years and continued shifts in 2025, we at William Blair have worked hard to expand our platform and provide creative solutions.

    Watch the video
  • Headlines vs. Trendlines: Unpacking an Up-and-Down First Quarter

    2025 began with a record-setting January, but gave way to a quiet March.

    Read more
  • The Quarterly Rx: Q1 2025 U.S. Biopharma Recap

    On Groundhog Day 2025, Punxsutawney Phil saw his shadow and, as per tradition, predicted six more weeks of winter. That proved apropos of biopharma’s performance in the first quarter of 2025, as the sector finds itself reliving existential anxieties.

    Read more
  • William Blair Private Capital Advisory: 2025 Secondary Market Report

    After an exceptional 2024—with global secondary volume growing approximately 40% from 2023—market insiders remain bullish and expect $175 billion in global transaction volume this year.

    Read more
  • Five Highlights of Rollover Equity and Management-Equity Incentives

    Owner-operators seeking to sell their companies are increasingly being offered rollover equity and management-equity incentives—to keep them committed to the company’s ongoing success.

    Read more
  • Aviation Services Industry Update

    U.S. general aviation and business jet activity finished 2024 on a strong note—and global airline industry revenues are projected to exceed $1 trillion for the first time in 2025.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures